NZYM B Novozymes A/S Class B

As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero.  

COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to SBTi’s new Corporate Net-Zero Standard by having a net-zero by 2050 science-based target verified by the SBTi.

“Novozymes is dedicated to building a net-zero future and accelerating decarbonization across our value chain. As a global leader, we embrace our leadership responsibility by setting the tone and leading by example together with less than 100 companies – across sectors – in the world, who has now obtained validation of their long-term net-zero targets for scope 1, 2, and 3 by SBTi. My hope is that this will inspire others to act,” says Ester Baiget, President & CEO and continues: 

“We have a long history of bold sustainability commitments, and we are ready to take our commitments to the next level. We will reach for net-zero by 2050 and we accelerate our 2025 renewable electricity target. And our work to reduce carbon emissions from our operations goes beyond shifting to renewable electricity. We are also introducing efforts to – where possible – give back parts of our excess industrial heat to our local communities.”



Novozymes validated targets

While more than 2,000 companies have SBTi commitments, less than 100 companies have a net-zero science-

based target verified by SBTi in per November 10th, 2022. Novozymes is one of them and is committed to SBTi’s new Corporate Net-Zero Standard by having a net-zero by 2050 science-based target verified by the SBTi.

The updated SBTi validated commitments are as follows:  

 2025 targetUpdated near-term target Long-term target
Scopes 1 + 2Purchase 100% renewable electricity (this target was previously set to 2030)

 



 
Reduce absolute CO2 emissions from operations by 75% by 2030 (pc. 1,2)

(previously 50% reduction in Scopes 1+2+3), (pc. 3)
Net-zero by 2050
Scope 3 Reduce absolute CO2 emissions from supply chain by 35% by 2030 (pc. 1,2)

(previously 50% reduction in Scopes 1+2+3), (pc. 3)



  1. Novozymes commits to reach net zero GHG emissions across the value chain by 2050 from a 2018 base year. Near-Term Targets: Novozymes commits to reduce absolute scope 1 and 2 GHG emissions 75% by 2030 from a 2018 base year*. Novozymes also commits to increase annual sourcing of renewable electricity from 37% in 2018 to 100% by 2025. Novozymes further commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations and business travel 35% by 2030 from a 2018 base year. Long-Term Targets: Novozymes commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2018 base year*. Novozymes also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations and business travel 90% within the same timeframe. *The targets boundary includes biogenic emissions and removals associated with the use of bioenergy.
  2. Direct emissions reductions (decarbonization) will be prioritized, and all residual emissions will be neutralized (if applicable) in line with SBTi criteria before reaching net-zero emissions.
  3. The total amount of scope 3 emissions is larger than scopes 1+2. Combined, 75% in scopes 1+2 and 35% in scope 3 is equivalent to 50% reduction across scope 1+2+3.

About the Science Based Targets initiative and the Corporate Net-Zero standard

Established in 2015, the Science Based Targets initiative (SBTi) is a collaboration between CDP, the UN Global Compact, World Resource Institute (WRI) and the World Wild Fund for Nature (WWF).



At the end of 2021, more than 2,200 companies across 70 countries and 15 industries, representing more than one third ($38 trillion) of the global market capitalization, had approved emission reduction targets or commitments with the SBTi. The SBTi was established to help companies set emission reduction targets in line with what the latest climate science deems necessary to meet the goals of the Paris Agreement thereby limiting global warming to 1.5°C.

In 2021, the SBTi developed and launched its Corporate Net-Zero Standard – the world’s first framework for corporate net-zero target setting in line with climate science. According to the SBTi, rapid, deep cuts to value chain emissions are the most effective and scientifically sound way to limit global temperature rise to 1.5°C.

This is the central focus of the Net-Zero Standard.

The Net-Zero Standard covers a company’s entire value chain emissions, including those produced by their own processes (scope 1), purchased electricity, steam, and heat (scope 2) and resulting from activities not owned or controlled by Novozymes, but which we impact in our value chain (scope 3). 

About Novozymes

Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow.



NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15 billion turnover • 30+ industries • 700+ products

   
Media Relations  
Lina Danstrup,

Head of Media Relations

Phone:

  
   








1

2

3

4



Attachment



EN
10/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch